Opinion: A role for placebo therapy in psychogenic movement disorders

Nature Reviews Neurology

Volumn 9, Issue 6, 2013, Pages 351-356

  Rommelfanger, Karen S ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NALOXONE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

BENEFICENCE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONVERSION DISORDER; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC TEST; DISEASE EXACERBATION; HEALTH CARE POLICY; HEALTH PRACTITIONER; HUMAN; MEDICAL ETHICS; MEDICAL PRACTICE; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPHYSIOLOGY; NONHUMAN; NONMALEFICENCE; PARAMEDICAL EDUCATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT REFERRAL; PATIENT SAFETY; PHYSIOTHERAPY; PLACEBO EFFECT; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOGENIC MOVEMENT DISORDER; PSYCHOPHYSIOLOGY; REVIEW; SOCIAL BEHAVIOR; SYMPTOM; THERAPY EFFECT; TRANSCRANIAL MAGNETIC STIMULATION;

HUMANS; MOVEMENT DISORDERS; PLACEBO EFFECT; PLACEBOS; PSYCHOPHYSIOLOGIC DISORDERS;

EID: 84878941871     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.65     Document Type: Review

References (49)

1. Kranick, S. M., Gorrindo, T. & Hallett, M. Psychogenic movement disorders and motor conversion: a roadmap for collaboration between neurology and psychiatry. Psychosomatics 52, 109-116 (2011).
2. Nowak, D. A. & Fink, G. R. Psychogenic movement disorders: aetiology, phenomenology, neuroanatomical correlates and therapeutic approaches. Neuroimage 47, 1015-1025 (2009).
3. Miyasaki, J. M., Sa, D. S., Galvez-Jimenez, N. & Lang, A. E. Psychogenic movement disorders. Can. J. Neurol. Sci. 30 (Suppl 1), S94-S100 (2003).
4. Anderson, K. E. et al. Impact of psychogenic movement disorders versus Parkinson's on disability, quality of life, and psychopathology. Mov. Disord. 22, 2204-2209 (2007).
5. Hinson, V. K. & Haren, W. B. Psychogenic movement disorders. Lancet Neurol. 5, 695-700 (2006).
6. Rommelfanger, K. S. Attitudes on mind over matter: physician views on the role of placebo in psychogenic disorders. AJOB Neurosci. (in press).
7. Fässler, M., Meissner, K., Schneider, A. & Linde, K. Frequency and circumstances of placebo use in clinical practice-a systematic review of empirical studies. BMC Med. 8, 15 (2010).
8. Sherman, R. & Hickner, J. Academic physicians use placebos in clinical practice and believe in the mind-body connection. J. Gen. Intern. Med. 23, 7-10 (2008).
9. Tilburt, J. C., Emanuel, E. J., Kaptchuk, T. J., Curlin, F. A. & Miller, F. G. Prescribing "placebo treatments": results of national survey of US internists and rheumatologists. BMJ 337, a1938 (2008).
10. Goodwin, J. S., Goodwin, J. M. & Vogel, A. V. Knowledge and use of placebos by house officers and nurses. Ann. Intern. Med. 91, 106-110 (1979).
11. Voon, V. et al. The involuntary nature of conversion disorder. Neurology 74, 223-228 (2010).
12. Kobayashi, K., Lang, A. E., Hallett, M. & Lenz, F. A. Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. Mov. Disord. 26, 1348-1352 (2011).
13. Espay, A. J. et al. Cortical and spinal abnormalities in psychogenic dystonia. Ann. Neurol. 59, 825-834 (2006).
14. Morgante, F. et al. Abnormal tactile temporal discrimination in psychogenic dystonia. Neurology 77, 1191-1197 (2011).
15. Quartarone, A. et al. Abnormal sensorimotor plasticity in organic but not in psychogenic dystonia. Brain 132, 2871-2877 (2009).
16. Voon, V. et al. Emotional stimuli and motor conversion disorder. Brain 133, 1526-1536 (2010).
17. Voon, V., Brezing, C., Gallea, C. & Hallett, M. Aberrant supplementary motor complex and limbic activity during motor preparation in motor conversion disorder. Mov. Disord. 26, 2396-2403 (2011).
18. Espay, A. J. et al. Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: an international survey of movement disorder society members. Mov. Disord. 24, 1366-1374 (2009).
19. Gupta, A. & Lang, A. E. Psychogenic movement disorders. Curr. Opin. Neurol. 22, 430-436 (2009).
20. Factor, S. A., Podskalny, G. D. & Molho, E. S. Psychogenic movement disorders: frequency, clinical profile, and characteristics. J. Neurol. Neurosurg. Psychiatry 59, 406-412 (1995).
21. Czarnecki, K. & Hallett, M. Functional (psychogenic) movement disorders. Curr. Opin. Neurol. 25, 507-512 (2012).
22. Williams, D. T., Ford, B. & Fahn, S. Phenomenology and psychopathology related to psychogenic movement disorders. Adv. Neurol. 65, 231-257 (1995).
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders®, 4th edn, text revision (American Psychiatric Publishing, 2000).
24. Feinstein, A., Stergiopoulos, V., Fine, J. & Lang, A. E. Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. Neuropsychiatry Neuropsychol. Behav. Neurol. 14, 169-176 (2001).
25. Jankovic, J., Vuong, K. D. & Thomas, M. Psychogenic tremor: long-term outcome. CNS Spectr. 11, 501-508 (2006).
26. Salinsky, M., Spencer, D., Boudreau, E. & Ferguson, F. Psychogenic nonepileptic seizures in US veterans. Neurology 77, 945-950 (2011).
27. Thomas, M., Vuong, K. D. & Jankovic, J. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat. Disord. 12, 382-387 (2006).
28. Fahn, S. & Williams, D. T. Psychogenic dystonia. Adv. Neurol. 50, 431-455 (1988).
29. Baik, J. S., Han, S. W., Park, J. H. & Lee, M. S. Psychogenic paroxysmal dyskinesia: the role of placebo in the diagnosis and management. Mov. Disord. 24, 1244-1245 (2009).
30. Van Nuenen, B. F., Wohlgemuth, M., Wong Chung, R. E., Abdo, W. F. & Bloem, B. R. Acupuncture for psychogenic movement disorders: treatment or diagnostic tool? Mov. Disord. 22, 1353-1355 (2007).
31. Shamy, M. C. The treatment of psychogenic movement disorders with suggestion is ethically justified. Mov. Disord. 25, 260-264 (2010).
32. Bostick, N. A., Sade, R., Levine, M. A. & Stewart, D. M. Placebo use in clinical practice: report of the American Medical Association Council on Ethical and Judicial Affairs. J. Clin. Ethics 19, 58-61 (2008).
33. Benedetti, F., Mayberg, H. S., Wager, T. D., Stohler, C. S. & Zubieta, J. K. Neurobiological mechanisms of the placebo effect. J. Neurosci. 25, 10390-10402 (2005).
34. Goetz, C. G. et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov. Disord. 23, 690-699 (2008).
35. Bendtsen, L., Mattsson, P., Zwart, J. A. & Lipton, R. B. Placebo response in clinical randomized trials of analgesics in migraine. Cephalalgia 23, 487-490 (2003).
36. Dworkin, R. H., Katz, J. & Gitlin, M. J. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology 65 (Suppl. 4), S7-S19 (2005).
37. Lidstone, S. C. et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch. Gen. Psychiatry 67, 857-865 (2010).
38. Zubieta, J. K. et al. Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J. Neurosci. 25, 7754-7762 (2005).
39. Benedetti, F. et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat. Neurosci. 7, 587-588 (2004).
40. Amanzio, M. & Benedetti, F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J. Neurosci. 19, 484-494 (1999).
41. Nolan, T. A., Price, D. D., Caudle, R. M., Murphy, N. P. & Neubert, J. K. Placebo-induced analgesia in an operant pain model in rats. Pain 153, 2009-2016 (2012).
42. Pollo, A., Vighetti, S., Rainero, I. & Benedetti, F. Placebo analgesia and the heart. Pain 102, 125-133 (2003).
43. Diederich, N. J. & Goetz, C. G. The placebo treatments in neurosciences: new insights from clinical and neuroimaging studies. Neurology 71, 677-684 (2008).
44. Benedetti, F. Placebo analgesia. Neurol. Sci. 27 (Suppl. 2), S100-S102 (2006).
45. Enck, P., Benedetti, F. & Schedlowski, M. New insights into the placebo and nocebo responses. Neuron 59, 195-206 (2008).
46. Kaptchuk, T. J. et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE 5, e15591 (2010).
47. Lynöe, N., Mattsson, B. & Sandlund, M. The attitudes of patients and physicians towards placebo treatment-a comparative study. Soc. Sci. Med. 36, 767-774 (1993).
48. Finniss, D. G., Kaptchuk, T. J., Miller, F. & Benedetti, F. Biological, clinical, and ethical advances of placebo effects. Lancet 375, 686-695 (2010).
49. Hallett, M. Psychogenic movement disorders: a crisis for neurology. Curr. Neurol. Neurosci. Rep. 6, 269-271 (2006).